Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PMN310

Monoclonal antibody · developed by ProMis Neurosciences

Phase 1 Most advanced trial
PMN Developer
1 Registered trials

What is PMN310?

PMN310 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. It is studied in early-onset Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Neurology
Developer
ProMis Neurosciences, Inc (PMN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06750432 Phase 1 Alzheimer Disease, Early Onset Active not recruiting PMN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer Disease, Early Onset

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PMN page.

Follow PMN, the company behind PMN310

See PMN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PMN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.